Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of flumazenil on recovery after outpatient endoscopy: a placebo-controlled trial
Autore:
Chang, AC; Solinger, MA; Yang, DT; Chen, YK;
Indirizzi:
Loma Linda Univ, Med Ctr, Div Gastroenterol, Dept Med, Loma Linda, CA 92350 Loma Linda Univ Loma Linda CA USA 92350 l, Dept Med, Loma Linda, CA 92350
Titolo Testata:
GASTROINTESTINAL ENDOSCOPY
fascicolo: 5, volume: 49, anno: 1999,
pagine: 573 - 579
SICI:
0016-5107(199905)49:5<573:IOFORA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
UPPER GASTROINTESTINAL ENDOSCOPY; BENZODIAZEPINE ANTAGONIST; MIDAZOLAM; DIAZEPAM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Chen, YK Loma Linda Univ, Med Ctr, Div Gastroenterol, Dept Med, Loma Linda, CA 92350 Loma Linda Univ Loma Linda CA USA 92350 ed, Loma Linda, CA 92350
Citazione:
A.C. Chang et al., "Impact of flumazenil on recovery after outpatient endoscopy: a placebo-controlled trial", GASTROIN EN, 49(5), 1999, pp. 573-579

Abstract

Background: Flumazenil is an imidazobenzodiazepine that blocks the centraleffects of benzodiazepines by competitive interaction at the receptor level. In this study we assessed the impact of flumazenil use on postsedation observation time in outpatients undergoing endoscopy. Methods: Sixty outpatients received midazolam for conscious sedation and were randomized after endoscopy to receive intravenous flumazenil (0.1 mg/mL) or placebo until awake or a total of 10 mL was given. All patients were assessed using various psychomotor and cognitive tests at baseline and at 5,15, 30, 45 and 60 minutes after flumazenil or placebo was administered. Results: The two groups were similar in age, gender, midazolam dose (mg/kg), vital signs, and baseline parameters. The average dose of flumazenil given was 0.41 mg. Sedation scores returned to presedation levels earlier in the flumazenil group, with significant differences compared to placebo at 5 minutes (84.6% vs. 24.2%), 15 minutes (88.5% vs. 57.6%) and 30 minutes (96.2% vs. 66.7%). Other parameters tested were not significantly different forpatients receiving placebo compared to those given flumazenil. Sedation scores returned to baseline earlier than other psychomotor and cognitive tests in both groups. Flumazenil reduced the mean observation time from 23.5 minutes to 8.3 minutes (p < 0.0005), a difference of 15.2 minutes (64.7%) based on sedation score. Conclusions: Flumazenil significantly reduces postsedation observation time. Actual cost savings will vary depending on staff end facility capacity, patient volume, flumazenil cost, and unit cost of observation time.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:08:42